Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone replacement therapy: consensus and controversies.

Panminerva medica·2014
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva ginecologica·2013
Same author

Comparison of estrogen and androgen levels after oral estrogen replacement therapy.

The Journal of reproductive medicine·2002
Same author

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Annals of internal medicine·2001
Same author

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.

Fertility and sterility·2001
Same author

Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.

Menopause (New York, N.Y.)·2001
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
Same journal

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Individualizing hormone-therapy according to cardiovascular risk.

D Shoupe1

  • 1Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. shoupe@usc.edu

Minerva Medica
|October 9, 2012
PubMed
Summary
This summary is machine-generated.

Hormone therapy offers significant benefits for most healthy women under 60 initiating treatment within 10 years of menopause. Special care is needed for women outside these guidelines or with cardiovascular disease risks.

More Related Videos

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Experiment Videos

Last Updated: May 18, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Area of Science:

  • Reproductive Endocrinology
  • Cardiovascular Health
  • Menopause Management

Background:

  • Growing consensus supports hormone therapy (HT) for healthy, low-risk women.
  • Specific age and time-since-menopause windows are critical for optimal benefit-risk.
  • Cardiovascular disease (CVD) risk factors necessitate individualized HT approaches.

Purpose of the Study:

  • To evaluate the benefit-to-risk profile of hormone therapy.
  • To identify specific patient populations requiring special considerations for hormone therapy initiation.
  • To inform clinical decision-making regarding hormone therapy in diverse menopausal populations.

Main Methods:

  • Review of current clinical consensus and guidelines.
  • Analysis of epidemiological data on hormone therapy outcomes.
  • Risk-benefit assessment based on age and time since menopause.

Main Results:

  • High benefit-to-risk ratio for hormone therapy in healthy women <60 years old within 10 years of menopause.
  • Increased risks or altered benefits for women outside these parameters.
  • Cardiovascular risk factors significantly modify the hormone therapy benefit-risk assessment.

Conclusions:

  • Hormone therapy is highly beneficial for a defined group of healthy menopausal women.
  • Individualized assessment is crucial for women with cardiovascular risks or outside standard initiation criteria.
  • Further research may be needed to refine HT recommendations for specific subgroups.